635702-24-8

Basic information

• Product Name: (4-(5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol
• Synonyms: (4-(5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol;[4-[5-[4-(2-Methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]methanol;BenzeneMethanol, 4-[5-[4-(2-Methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl]-
• CAS NO: 635702-24-8
• Molecular Formula: C₁₉H₂₀N₂O₂
• Molecular Weight: 308.37
• Mol File: 635702-24-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 479.852 °C at 760 mmHg
• Flash Point: 244.006 °C
• Appearance: /
• Density: 1.145
• PKA: 13?+-.0.10(Predicted)
• CAS DataBase Reference: (4-(5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-(5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol(635702-24-8)
• EPA Substance Registry System: (4-(5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol(635702-24-8)

Safety Data

• Hazardous Substances Data: 635702-24-8(Hazardous Substances Data)

Usage

General Description

The chemical (4-(5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol is a compound with a complex structure that contains a phenyl ring linked to a 1,2,4-oxadiazol-3-yl ring, which in turn is connected to an isobutylphenyl group. Additionally, a methanol group is attached to the central phenyl ring. This chemical is likely to have diverse biological and pharmacological properties due to the presence of multiple functional groups. However, further research is needed to fully understand its potential uses and effects.

Upstream product

• 635702-23-7 (E)-N′-hydroxy-4-(hydroxymethyl)benzimidamide 
• 38861-88-0 4-isobutylbenzoic acid 
• 874-89-5 4-Cyanobenzyl alcohol 
• 635702-23-7 N-hydroxy-4-(hydroxymethyl)benzenecarboximidamide 
• 2592-95-2 benzotriazol-1-ol 
• 1233243-49-6 (Z)-N'-hydroxy-4-(hydroxymethyl)benzimidamide 

Downstream Products

• 635701-88-1 4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]-benzaldehyde 
• 635701-59-6 1-{4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]-benzyl}-3-azetidine carboxylic acid 

Relevant articles and documents

IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1 P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1 P1 receptor.

COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF

Provided are: a compound represented by formula (I): (wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain; L represents a hydrogen atom or a substituent; X represents amino which may have a substituent(s), or a heterocylcic group which contains at least one nitrogen atom and which may have a substituent(s); n represents 0 to 3, in which when n is 2 or more, a plurality of ring A's may be the same or different from one another); a salt thereof; an N-oxide form thereof; a solvate thereof; a prodrug thereof; and a medicament which includes those. The compound represented by formula (I) is capable of binding S1P receptors (in particular, EDG-1 and/or EDG-6), and useful for preventing and/or treating rejection in transplantation, autoimmune diseases, allergic diseases, etc.

Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3

A class of 3,5-diphenyl-1,2,4-oxadiazole based compounds have been identified as potent sphingosine-1-phosphate-1 (S1P1) receptor agonists with minimal affinity for the S1P2 and S1P3 receptor subtypes. Analogue 26 (S1P1 IC50 = 0.6 nM) has an excellent pharmacokinetics profile in the rat and dog and is efficacious in a rat skin transplant model, indicating that S1P3 receptor agonism is not a component of immunosuppressive efficacy.